Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor: Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske

Publikováno v: The Lancet Haematology. 9:e810-e821

Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Autor: Daniela Weber, Walter Fiedler, Hans Salwender, Richard F. Schlenk, Katharina Götze, Gerald Wulf, Maral Saadati, Hartmut Döhner, Bernd Hertenstein, Axel Benner, Jörg Westermann, Michael Lübbert, Anika Schrade, Mark Ringhoffer, Helmut R. Salih, Felicitas Thol, Sigrid Machherndl-Spandl, Karin Mayer, Frauke Theis, Peter Paschka, Julia Krzykalla, Verena I. Gaidzik, Michael Heuser, Thomas Schroeder, Arnold Ganser, Hans-Joachim Tischler, Michael W.M. Kühn, Lars Bullinger, Konstanze Döhner, Lars Fransecky

Publikováno v: Blood. 138:692-692

BACKGROUND: Midostaurin is a first-generation, type I multi-targeted kinase inhibitor with inhibitory activity against FLT3-ITD and -TKD mutations. Midostaurin is approved by FDA and EMA in combination with intensive induction and consolidation chemo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ae682bb0b321e1b16308dd328126481
https://doi.org/10.1182/blood-2021-147256

Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey

Autor: Wolfgang Knauf, Maximilian Merz, Wolfram Poenisch, Lenka Kellermann, Joern Kohnke, Hartmut Goldschmidt, Hans-Joachim Tischler

Publikováno v: Annals of hematology. 96(6)

A nationwide, multi-institutional survey was performed in 2011 and 2015 to analyze routine practice for myeloma patients outside clinical trials in Germany. We contacted university hospitals, community hospitals, and office-based hematologists in ord

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae9ac67573fc84af5b489dc1d6402d8
https://pubmed.ncbi.nlm.nih.gov/28409228

The CD 16 Molecule on NK Cells Is Different from the PIG-Linked Structure on PMNs1

Autor: Hans-Joachim Tischler, Jörg Schubert, Delany P, Peter Uciechowski, Reinhold E. Schmidt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8a503ba17ebb62bbf5f4e2705574ce3
https://doi.org/10.1159/000418879

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Autor: Stephan Kremers, Claudia D. Baldus, Hartmut Döhner, Frank Heits, Andreas Hochhaus, Martin Goerner, Richard F. Schlenk, Gerhard Ehninger, Ralph Naumann, Mathias Hänel, Stefan W. Krause, Markus P. Radsak, Katharina Goetze, Harald Biersack, Thomas Kubin, Hubert Serve, Mark Ringhoffer, Christian Thiede, Ulrich Duehrsen, Nadine Albers, Gregor Aschauer, Sonja Martin, Albrecht Reichle, Tilmann Bochtler, Eva Lengfelder, Joerg Mezger, Hartmut Link, Helmut R. Salih, Jochen Greiner, Uwe Platzbecker, Andreas Jakob, M. Sauer, Sigrid Machherndl-Spandl, Christoph Röllig, Michael Heuser, Florian Nolte, Nadezda Basara, Elisabeth Koller, Hans-Joachim Tischler, Kerstin Schäfer-Eckart, Michael Kramer, Maike de Wit, Dominik Wolf, Martin Bornhäuser, Dorit Kuerschner, M. Wattad, Tim H. Brümmendorf

Publikováno v: Blood. 128:2815-2815

Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5934ccb3a66e3591a5d59cbc6f9f9964
https://doi.org/10.1182/blood.v128.22.2815.2815